<DOC>
	<DOCNO>NCT01767103</DOCNO>
	<brief_summary>Multi-center , non-randomized , open-label , single-dose , parallel group study determine effect impair hepatic function PK deferiprone 3-O-glucuronide metabolite follow single oral dose 33mg/kg Ferriprox® .</brief_summary>
	<brief_title>An Open-label , Non-randomized , Parallel Group Study Subjects With Mild Moderate Hepatic Insufficiency Healthy Volunteers</brief_title>
	<detailed_description>Post-marketing study evaluate effect impair hepatic function pharmacokinetics ( PK ) deferiprone 3-O-glucuronide metabolite safety Ferriprox® subject mild moderate hepatic impairment compare healthy volunteer .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Main All subject : 1 . Adult male female , 18 75 year age ( inclusive ) ; 2 . Body weight ≥ 50 kg ; 3 . Body mass index ( BMI ) 19 32 kg/mE2 ( inclusive ) ; 4 . Absolute neutrophil count ( ANC ) &gt; 1.5x10E9/L ; Healthy volunteer : 1 . Medically healthy clinically insignificant screen result ( e.g. , laboratory profile , medical history , vital sign , physical examination ) ; 2 . Matched hepatically impaired subject study age ( +/ 10 year ) , sex weight ( +/ 15 % BMI ) . Hepatically impaired subject : 1 . Considered clinically stable opinion Investigator ; 2 . Subjects different degree impair hepatic function assess ChildPugh classification score : mild ( Class A : 56 point ) moderate ( Class B : 79 point ) impair hepatic function . Main 1 . For subject hepatic impairment , fluctuate rapidly deteriorate hepatic function indicate clinical and/or laboratory sign hepatic impairment ( e.g . advanced ascites , infection ascites , fever , active gastrointestinal bleeding ) . 2 . Evidence liver impairment healthy volunteer : hepatitis B C ; aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , bilirubin , clot factor , serum protein consider clinically significant Investigator ; 3 . History presence significant clinically unstable respiratory , cardiovascular , pulmonary , hepatic ( except subject assign one hepatically impaired group ) , renal , hematologic , gastrointestinal , endocrine ( except subject hepatic impairment clinically stable treat diabetes , hypertension thyroid disorder ) , immunologic , dermatologic , neurologic , psychiatric disease ; 4 . Disorders surgery gastrointestinal tract may interfere drug absorption may otherwise influence PK investigational medicinal product ( e.g . resection small large intestine , febrile condition , chronic diarrhea , chronic vomiting , clinically unstable endocrine disease , severe infection , acute inflammation , etc . ) ; 5 . Received pharmacological agent another clinical trial within 28 day prior first dose study ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Liver Impairment</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Ferriprox®</keyword>
	<keyword>LI</keyword>
	<keyword>DFP</keyword>
	<keyword>Deferiprone</keyword>
</DOC>